Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Spruce Biosciences Inc.

Oppenheimer analyst initiated coverage with a Buy rating on Spruce Biosciences today and set a price target of $283.00. Currently, the analyst cons...

Spruce Biosciences (SPRB) Initiated with a Buy at Oppenheimer

Spruce Biosciences ( ($SPRB) ) just unveiled an announcement. On December 11, 2025, Spruce Biosciences, Inc. appointed Keli Walbert as a Class I Di...

Spruce Biosciences Appoints Keli Walbert as Director

Spruce Biosciences ( ($SPRB) ) has provided an update. Spruce Biosciences announced that on December 11, 2025, Tiba Aynechi, Ph.D. resigned from it...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SPRB	$84.00	+0.31%	14.18K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SPRB	$84.00	+0.3%	14.18K
3
4
5
6

SPRB

SPRB

No Data Available

Get Spruce Biosciences Inc. Data in Excel

Get Spruce Biosciences Inc. Data in Excel